Biocardia Company Insiders

BCDA Stock  USD 2.10  0.05  2.44%   
About 92 percent of all Biocardia's insiders are aggressively buying. The analysis of the overall insider sentiment regarding Biocardia suggests that a fairly large number of insiders are very bullish. Biocardia employs about 16 people. The company is managed by 6 executives with a total tenure of roughly 18 years, averaging almost 3.0 years of service per executive, having 2.67 employees per reported executive.
Peter Altman  CEO
President CEO, Principal Executive Officer, Director
David McClung  President
Principal Financial and Accounting Officer, Vice President - Finance

Insider Sentiment 92

 Aggressively Buying

 
Selling
 
Buying

Latest Trades

2025-02-07Peter AltmanAcquired 600 @ 2.48View
2025-01-29Peter AltmanAcquired 500 @ 2.4View
2024-12-23Peter AltmanAcquired 1000 @ 2.06View
2024-12-20Edward M GillisDisposed 3257 @ 2View
2024-12-05Peter AltmanAcquired 250 @ 2.22View
2024-11-15Peter AltmanAcquired 1350 @ 1.87View
2024-07-01Peter AltmanAcquired 300 @ 3.05View
2024-06-28Peter AltmanAcquired 200 @ 2.99View
2024-06-21Peter AltmanAcquired 500 @ 3.29View
2024-06-14Peter AltmanAcquired 500 @ 3.52View
2024-06-10Peter AltmanAcquired 1000 @ 3.36View
2024-04-19Peter AltmanAcquired 183 @ 5.55View
2024-03-28Peter AltmanAcquired 33 @ 5.85View
Monitoring Biocardia's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biocardia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.

Biocardia's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Biocardia's future performance. Based on our forecasts, it is anticipated that Biocardia will maintain a workforce of about 16 employees by March 2025.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Biocardia Management Team Effectiveness

The company has return on total asset (ROA) of (0.9691) % which means that it has lost $0.9691 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.3789) %, meaning that it created substantial loss on money invested by shareholders. Biocardia's management efficiency ratios could be used to measure how well Biocardia manages its routine affairs as well as how well it operates its assets and liabilities. At present, Biocardia's Return On Capital Employed is projected to increase significantly based on the last few years of reporting. The current year's Return On Equity is expected to grow to 6.82, whereas Return On Tangible Assets are projected to grow to (4.23). At present, Biocardia's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 436.7 K, whereas Total Assets are forecasted to decline to about 3.3 M.
As of February 26, 2025, Common Stock Shares Outstanding is expected to decline to about 1.4 M. In addition to that, Net Loss is expected to decline to about (11.3 M)

Biocardia Workforce Comparison

Biocardia is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 819. Biocardia claims roughly 16.0 in number of employees contributing just under 2% to equities under Health Care industry.

Biocardia Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biocardia insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biocardia's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Biocardia insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-12-01
2.2
11
5
 76,017 
 59,150 
2023-06-01
4.0
12
3
 692,531 
 73,009 
2022-06-01
0.3333
1
3
 31,085 
 47,303 
2021-06-01
1.5
9
6
 376,594 
 93,703 
2020-12-01
9.0
18
2
 46,398 
 11,635 
2020-06-01
10.25
41
4
 851,772 
 36,393 
2020-03-01
1.1429
8
7
 10,201 
 12,469 
2019-12-01
1.6667
5
3
 10,100 
 30,000 
2019-09-01
2.1429
30
14
 822,449 
 641,825 
2019-03-01
1.25
5
4
 2,318 
 2,268 
2018-12-01
9.6667
29
3
 15,523,445 
 833,333 
2018-06-01
1.5
6
4
 40,664 
 36,664 
2018-03-01
4.0
16
4
 918,594 
 20,444 
2017-12-01
1.0
4
4
 1,630,716 
 1,630,716 
2016-12-01
0.1
2
20
 172,600 
 39,853,037 
2016-06-01
0.25
1
4
 114,937,148 
 103,917,532 
2011-06-01
3.0
3
1
 127,185 
 0.00 
2008-09-01
0.15
3
20
 28,016,949 
 1,565,000 
2005-03-01
0.25
1
4
 600,000 
 84,490 

Biocardia Notable Stakeholders

A Biocardia stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Biocardia often face trade-offs trying to please all of them. Biocardia's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Biocardia's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Peter AltmanPresident CEO, Principal Executive Officer, DirectorProfile
David McClungPrincipal Financial and Accounting Officer, Vice President - FinanceProfile
Edward GillisSenior DevicesProfile
Ian McNieceChief OfficerProfile
Sujith ShettyChief RegulatoryProfile
Sujith MBBSChief RegulatoryProfile

About Biocardia Management Performance

The success or failure of an entity such as Biocardia often depends on how effective the management is. Biocardia management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Biocardia management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Biocardia management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(4.45)(4.23)
Return On Capital Employed 16.88  17.72 
Return On Assets(4.45)(4.23)
Return On Equity 6.50  6.82 
Please note, the presentation of Biocardia's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biocardia's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Biocardia's management manipulating its earnings.

Biocardia Workforce Analysis

Traditionally, organizations such as Biocardia use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Biocardia within its industry.

Biocardia Manpower Efficiency

Return on Biocardia Manpower

Revenue Per Employee29.8K
Revenue Per Executive79.5K
Net Loss Per Employee723.2K
Net Loss Per Executive1.9M

Complementary Tools for Biocardia Stock analysis

When running Biocardia's price analysis, check to measure Biocardia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocardia is operating at the current time. Most of Biocardia's value examination focuses on studying past and present price action to predict the probability of Biocardia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biocardia's price. Additionally, you may evaluate how the addition of Biocardia to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Volatility Analysis
Get historical volatility and risk analysis based on latest market data